Skip to content

H.R. 2408 · 118th Congress (2023–2025)

Access to Innovative Treatments Act of 2023

This bill requires the Centers for Medicare & Medicaid Services (CMS) to review adverse national coverage determinations of drugs under Medicare within 30 days of receiving a request to do so. (Under the bill, adverse national coverage determinations are denials or limitations of coverage that are inconsistent with the drug's approval by the Food and Drug Administration.) The bill's requirements do not apply if the CMS already conducted such a review within a two-year period.

The bill also prohibits the CMS from applying prior coverage determinations that were made for drugs before they were approved by the FDA if such determinations are inconsistent with the drug's approval.

Show official title

To amend title XVIII of the Social Security Act to provide a review process for adverse national coverage determinations with respect to drug coverage under the Medicare program.

Expired in House committee

Derived from the legislative history, not an official disposition.

Latest actionReferred to Health

This bill’s path

This is H.R. 2408’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed House

  3. Passed Senate

  4. Sent to President

  5. Signed into law

  6. Expired

Sponsor
Rep. Nanette Diaz Barragan (D-CA-44)
Cosponsors
1 cosponsor

1 original · 0 later

  1. Rep. John Joyce (R-PA-13)· Original · Mar 30, 2023
Policy area
Health

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in House

    Document: Introduced in House

    Sources
  2. Latest
    ▸ 3 committee actions · Mar 30, 2023 – Dec 17, 2024
    1. Referred to committee

      Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

      Sources
    2. Referred to Health

      Referred to the Subcommittee on Health.

      Sources
    3. Referred to Health

      Referred to the Subcommittee on Health.

      Sources
  3. Expired

    Introduced → Referred to House Health → No further action before the 118th Congress ended.

Committees

  1. HouseEnergy and CommerceReferred Mar 30, 2023
  2. HouseHealthReferred Apr 7, 2023
    1. Sep 19, 2023 · Meeting

  3. HouseWays and MeansReferred Mar 30, 2023
  4. HouseHealthReferred Dec 17, 2024

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in House
Titles (2)
  1. Access to Innovative Treatments Act of 2023

    Display title, Short title · Introduced in House

  2. To amend title XVIII of the Social Security Act to provide a review process for adverse national coverage determinations with respect to drug coverage under the Medicare program.

    Official title · Introduced in House